Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Novel cancer vaccine based on genes of Salmonella pathogenicity island 2
International Journal of Cancer, Volume 126, No. 11, Year 2010
Notification
URL copied to clipboard!
Description
Although tumors express potentially immunogenic tumor-associated antigens (TAAs), cancer vaccines often fail because of inadequate antigen delivery and/or insufficient activation of innate immunity. Engineering nonpathogenic bacterial vectors to deliver TAAs of choice may provide an efficient way of presenting TAAs in an immunogenic form. In this study, we used genes of Salmonella pathogenicity island 2 (SPI2) to construct a novel cancer vaccine in which a TAA, survivin, was fused to SseF effector protein and placed under control of SsrB, the central regulator of SPI2 gene expression. This construct uses the type III secretion system (T3SS) of Salmonella and allows preferential delivery of tumor antigen into the cytosol of antigen-presenting cells for optimal immunogenicity. In a screen of a panel of attenuated strains of Salmonella, we found that a double attenuated strain of Salmonella typhimurium, MvP728 (purD/htrA), was not toxic to mice and effectively expressed and translocated survivin protein inside the cytosol of murine macrophages. We also found that a ligand for CD1d-reactive natural killer T (NKT) cells, α- glucuronosylceramide (GSL1), enhanced MvP728-induced interleukin-12 production in human dendritic cells and that in vivo coadministration of a NKT ligand with MvP728-Llo or MvP728-survivin enhanced effector-memory cytotoxic T lymphocyte (CTL) responses. Furthermore, combined use of MvP728-survivin with GSL1 produced antitumor activity in mouse models of CT26 colon carcinoma and orthotopic DBT glioblastoma. Therefore, the use of TAA delivery via SPI-2-regulated T3SS of Salmonella and NKT ligands as adjuvants may provide a foundation for new cancer vaccines. © 2009 UICC.
Authors & Co-Authors
Xiong, Guosheng
United States, Los Angeles
Keck School of Medicine of Usc
Husseiny, Mohamed Ibrahim
United States, Los Angeles
Keck School of Medicine of Usc
Egypt, Zagazig
Faculty of Pharmacy
Song, Liping
United States, Houston
Bcm Center for Cell and Gene Therapy
Erdreich-Epstein, Anat
United States, Los Angeles
Keck School of Medicine of Usc
Shackleford, Gregory M.
United States, Los Angeles
Keck School of Medicine of Usc
Seeger, Robert C.
United States, Los Angeles
Keck School of Medicine of Usc
Jäckel, Daniela
Germany, Erlangen
Infektionsbiologische Abteilung
Hensel, Michael T.
Germany, Erlangen
Universitätsklinikum Erlangen
Metelitsa, Leonid
United States, Houston
Bcm Center for Cell and Gene Therapy
Statistics
Citations: 85
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1002/ijc.24957
ISSN:
00207136
e-ISSN:
10970215
Research Areas
Cancer
Environmental
Genetics And Genomics
Infectious Diseases